D.E. Shaw & Co
CKPT

D.E. Shaw & Co’s Checkpoint Therapeutics CKPT Stock Holding History

D.E. Shaw & Co’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-29,695
Closed -$95K – 4315
2024
Q4 		$95K Sell
29,695
-58,727
-66% -$199K ﹤0.01% 4169
2024
Q3 		$198K Buy
88,422
+42,468
+92% +$98K ﹤0.01% 4162
2024
Q2 		$98.8K Sell
45,954
-62,658
-58% -$112K ﹤0.01% 4165
2024
Q1 		$223K Sell
108,612
-31,934
-23% -$63.7K ﹤0.01% 3882
2023
Q4 		$322K Buy
+140,546
New +$306K ﹤0.01% 3715
2022
Q4 		– Sell
-1,076
Closed -$11K – 4889
2022
Q3 		$11K Hold
1,076
– – ﹤0.01% 4915
2022
Q2 		$11K Sell
1,076
-581
-35% -$7.61K ﹤0.01% 5124
2022
Q1 		$29K Sell
1,657
-10,175
-86% -$219K ﹤0.01% 5280
2021
Q4 		$368K Buy
11,832
+4,869
+70% +$161K ﹤0.01% 4571
2021
Q3 		$230K Sell
6,963
-2,112
-23% -$62.4K ﹤0.01% 4500
2021
Q2 		$268K Buy
+9,075
New +$252K ﹤0.01% 4325

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

D.E. Shaw & Co's CKPT Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 29,695 shares — an estimated $95K sold.

D.E. Shaw & Co first reported a position in CKPT in Q2 2021 and held it in 11 quarters. The position peaked at $368K in Q4 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 29,695 Checkpoint Therapeutics shares in Q1 2025, an estimated $95K.
  • D.E. Shaw & Co first reported a position in Checkpoint Therapeutics in Q2 2021 and held it in 11 quarters.
  • D.E. Shaw & Co's Checkpoint Therapeutics position peaked at $368K in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.